Announcements
- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
- Idorsia takes steps to address short-term liquidity needs
- Idorsia thanks Guy Braunstein for his years of service as he retires
- US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration
- Idorsia and Viatris enter into a significant global research and development collaboration
- Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
- New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
- Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
- Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.13 |
---|---|
High | 19.57 |
Low | 18.13 |
Bid | 19.45 |
Offer | 20.74 |
Previous close | 19.54 |
Average volume | -- |
---|---|
Shares outstanding | 188.84m |
Free float | 120.56m |
P/E (TTM) | -- |
Market cap | 343.70m CHF |
EPS (TTM) | -2.11 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼